The treatment

AVLX-144

Clinical trials progressing

We are a biotechnology company developing innovative treatments for acute conditions such as acute ischemic stroke (AIS) and subarachnoid haemorrhage (SAH). In October 2020 we administered a first dose of our lead compound AVLX-144 to a human volunteer in a Phase 1 clinical study.

Acute ischemic stroke is a leading cause of death and disability worldwide with few treatment options available, while subarachnoid haemorrhage is a particular form of stroke and an orphan indication. Based on positive results from our extensive preclinical characterization of AVLX-144 and our first clinical trials results we are convinced that we have a unique opportunity to make a transformative difference for patients,

Current Status

AVLX-144

18

Stroke costs the United States an estimated $34 billion each year (which includes cost of healthcare, medicine, rehabilitation, and missed workdays)

18k

Stroke costs the United States an estimated $34 billion each year (which includes cost of healthcare, medicine, rehabilitation, and missed workdays)

124m

Stroke costs the United States an estimated $34 billion each year (which includes cost of healthcare, medicine, rehabilitation, and missed workdays)

18k

Stroke costs the United States an estimated $34 billion each year (which includes cost of healthcare, medicine, rehabilitation, and missed workdays)

Latest News

AVLX-144

A game-changing treatment for acute ischemic stroke

Acute ischemic stroke is a leading cause of death and disability worldwide with few treatment options available, while subarachnoid haemorrhage is a particular…

Read More

Promising Agent for Ischemic Stroke Now to Be Tested in Humans

A compound developed by Danish researchers from the University of Copenhagen could be the key to one of the greatest unsolved challenges in modern medicine.…

Read More

Get in touch